Telix H1 2026 Results: Investor Webcast Notification
Telix today advises that it will release its financial results for the half-year ended June 30, 2026 on Thursday August 20, 2026.
Telix Q2 2026 Revenue US$247M, Strong Momentum and Pipeline Progress
Telix provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026).
TLX101-Px (Pixlumi®) MAA Accepted in Europe
Telix today announces that the marketing authorization application (MAA) filed in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (brain cancer) imaging candidate, has been validated and accepted for review.
Notice of Annual General Meeting 2026
Telix announces its Annual General Meeting of shareholders to be held at
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
Telix today announces that the first patient has been dosed with TLX101-Tx (¹³¹I-iodofalan) in Telix’s pivotal IPAX BrIGHT trial, marking the first radiopharmaceutical therapy to enter Phase 3 development for glioblastoma, an aggressive form of brain cancer.
Telix and Regeneron Announce Strategic Radiopharma Collaboration
Telix and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN, “Regeneron”) today announce a collaboration to jointly develop and commercialize next generation radiopharmaceutical therapies.
FDA Accepts NDA for TLX101-Px (Pixclara®)
Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Company’s resubmitted New Drug Application (NDA) for TLX101-Px, (Pixclara®, Floretyrosine F 18 or 18F-FET), an investigational PET agent for the imaging of glioma (brain cancer), and has assigned a PDUFA goal date of September 11, 2026.
Telix Strengthens Board with Additional Director Appointments
Telix today announces two additional Non-Executive Director (NED) appointments, effective May 11, 2026, as part of Board expansion and succession planning
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
Telix provides a market update on its commercial and operational performance for the quarter ended March 31, 2026 (Q1 2026).
Telix Appoints David Gill as Non-Executive Director
Telix today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May 11, 2026. Mr. Gill is expected to be appointed Chair, succeeding Dr. Mark Nelson who will remain on the Board as a NED.